Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ABUS Arbutus Biopharma Corporation daily Stock Chart
ABUS [NASD]
Arbutus Biopharma Corporation
Healthcare | Biotechnology | Canada
financial highlights | statements
Index- P/E- EPS (ttm)-1.81 Insider Own5.80% Shs Outstand59.08M Perf Week-6.99%
Market Cap204.42M Forward P/E- EPS next Y-1.61 Insider Trans-0.12% Shs Float29.86M Perf Month-10.59%
Income-100.00M PEG- EPS next Q-0.40 Inst Own43.60% Short Float3.98% Perf Quarter-20.28%
Sales6.80M P/S30.06 EPS this Y74.20% Inst Trans-0.20% Short Ratio5.22 Perf Half Y-69.91%
Book/sh1.66 P/B2.08 EPS next Y-8.40% ROA-32.30% Target Price9.32 Perf Year-32.82%
Cash/sh2.40 P/C1.44 EPS next 5Y- ROE-72.90% 52W Range3.20 - 12.60 Perf YTD-9.66%
Dividend- P/FCF- EPS past 5Y-23.80% ROI-72.50% 52W High-72.54% Beta2.18
Dividend %- Quick Ratio11.40 Sales past 5Y-5.40% Gross Margin- 52W Low8.12% ATR0.31
Employees130 Current Ratio11.40 Sales Q/Q-76.80% Oper. Margin- RSI (14)40.36 Volatility7.82% 8.53%
OptionableYes Debt/Eq0.00 EPS Q/Q-130.80% Profit Margin- Rel Volume0.30 Prev Close3.54
ShortableYes LT Debt/Eq0.00 EarningsFeb 06 AMC Payout- Avg Volume227.90K Price3.46
Recom1.90 SMA20-8.78% SMA50-18.61% SMA200-48.74% Volume67,904 Change-2.26%
Oct-16-18Upgrade B. Riley FBR Neutral → Buy $11.50 → $9
Oct-15-18Upgrade Wedbush Underperform → Neutral $5
Oct-12-18Reiterated Chardan Capital Markets Buy $12 → $6.50
Jul-06-18Downgrade B. Riley FBR, Inc. Buy → Neutral $9 → $9
Mar-19-18Resumed Chardan Capital Markets Buy $8.25
Mar-19-18Downgrade Wedbush Outperform → Neutral $9 → $6
Jan-05-18Initiated B. Riley FBR, Inc. Buy $10
Apr-04-17Upgrade Chardan Capital Markets Neutral → Buy $3 → $6
Feb-01-17Reiterated Wedbush Outperform $13 → $10
Dec-13-16Downgrade Chardan Capital Markets Buy → Neutral $4 → $3
Nov-30-16Upgrade Chardan Capital Markets Neutral → Buy $4
Oct-14-16Upgrade Chardan Capital Markets Sell → Neutral $3
Aug-05-16Downgrade Leerink Partners Outperform → Mkt Perform
Jul-08-16Downgrade Chardan Capital Markets Neutral → Sell $3.25 → $2.75
Jun-16-16Upgrade Chardan Capital Markets Sell → Neutral $3.25
May-16-16Initiated Chardan Capital Markets Sell $3.25
Nov-06-15Reiterated RBC Capital Mkts Outperform $35 → $20
Sep-02-15Initiated JMP Securities Mkt Outperform
Jan-22-19 10:13AM  Can We See Significant Insider Ownership On The Arbutus Biopharma Corporation (NASDAQ:ABUS) Share Register? Simply Wall St.
Dec-23-18 03:40AM  Do Hedge Funds Love Arbutus Biopharma Corp (ABUS)? Insider Monkey
Dec-11-18 07:55AM  New Research Coverage Highlights Nokia, SecureWorks, National Western Life Group, Brookfield Asset Management, FormFactor, and Arbutus Biopharma Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Dec-08-18 10:03PM  Is PennyMac Financial Services Inc (PFSI) A Good Stock To Buy? Insider Monkey
Dec-05-18 11:20AM  Why Arbutus Biopharma Corporations (NASDAQ:ABUS) CEO Pay Matters To You Simply Wall St.
Nov-26-18 04:41PM  Arbutus Appoints Dr. Frank Torti as Chairman of its Board of Directors GlobeNewswire -5.60%
Nov-21-18 08:41AM  Options Traders Expect Huge Moves in Arbutus (ABUS) Stock Zacks +5.17%
Nov-07-18 04:01PM  Arbutus Reports 2018 Third Quarter Financial Results and Provides Corporate Update GlobeNewswire
Oct-31-18 08:30AM  Arbutus to Report Third Quarter 2018 Financial Results GlobeNewswire
Oct-22-18 08:30AM  Arbutus Names New Members to its Board of Directors GlobeNewswire
Oct-19-18 08:25AM  New Research Coverage Highlights Arbutus Biopharma, Tata Motors, Core-Mark Holding, Tenaris S.A, Addus HomeCare, and ZTO Express (Cayman) Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-17-18 02:25PM  What Kind Of Risk Should You Expect For Arbutus Biopharma Corporation (NASDAQ:ABUS)? Simply Wall St.
Oct-10-18 10:23AM  Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates Zacks -23.83%
08:00AM  Today's Research Reports on Trending Tickers: Arbutus Biopharma and Akcea Therapeutics ACCESSWIRE
Oct-09-18 03:23PM  Here's Why Arbutus Biopharma Corp. Is Tanking Today Motley Fool -33.99%
08:30AM  Arbutus Provides Update on HBV Development Programs and Announces Appointment of Dr. Gaston Picchio as Chief Development Officer GlobeNewswire
Oct-02-18 08:30AM  Arbutus to Present at Chardans Genetic Medicines Conference GlobeNewswire
Sep-24-18 09:00AM  Are Options Traders Betting on a Big Move in Arbutus (ABUS) Stock? Zacks
Aug-28-18 08:30AM  Arbutus to Participate at the 2018 B. Riley FBR Healthcare Conference GlobeNewswire
Aug-21-18 07:35AM  Consolidated Research: 2018 Summary Expectations for GSV Capital, NantHealth, Gold Fields, Sogou Inc. Sponsored ADR, Clementia Pharmaceuticals, and Arbutus Biopharma Fundamental Analysis, Key Performance Indications GlobeNewswire
Aug-13-18 08:30AM  Arbutus LNP Licensee Alnylam Announces FDA Approval of ONPATTRO (patisiran), for the Treatment of ATTR Amyloidosis GlobeNewswire
Aug-09-18 08:30AM  Arbutus to Present at the 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-02-18 04:00PM  Arbutus Reports 2018 Second Quarter Financial Results and Provides Corporate Update GlobeNewswire
02:30PM  Arbutus Biopharma Corporation to Host Earnings Call ACCESSWIRE
Jul-20-18 09:31AM  Arbutus Biopharma (ABUS) Shares March Higher, Can It Continue? Zacks
Jul-19-18 10:26AM  Harry Boxers three drug stocks to watch MarketWatch
08:30AM  Arbutus to Report Second Quarter 2018 Financial Results GlobeNewswire
Jul-14-18 02:02PM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jul-12-18 12:54PM  Harry Boxers four health-care stocks to watch MarketWatch +8.49%
Jul-10-18 07:00AM  Arbutus Presents Corporate Update on Key Milestones GlobeNewswire
Jul-07-18 07:15AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jul-06-18 10:59AM  Analyst Downgrades Arbutus Biopharma On Valuation After 80% Run Benzinga
09:02AM  Arbutus Biopharma (ABUS) Jumps: Stock Rises 9.6% Zacks
Jun-18-18 08:30AM  Arbutus Biopharma to Present at First Annual Roivant Pipeline Day GlobeNewswire +6.30%
Jun-07-18 05:44PM  Arbutus Strengthens Management Team With Appointment of David C. Hastings as New Chief Financial Officer GlobeNewswire
Jun-06-18 07:40AM  Research Report Identifies Diodes, Arbutus Biopharma, Radware, Immutep, Amarin, and SPS Commerce with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
May-07-18 07:10AM  Blog Exposure - Spectrum Pharma Inked Licensing Agreement with The University of Texas MD Anderson Cancer Center on Certain Methods of Use of Poziotinib ACCESSWIRE
May-03-18 05:28PM  Arbutus: 1Q Earnings Snapshot Associated Press
04:15PM  Merck Teams With Moderna To Take On One Of The Toughest Targets In Cancer Forbes
04:00PM  Arbutus Announces Corporate Update and First Quarter 2018 Financial Results GlobeNewswire
Apr-30-18 09:00AM  Arbutus Announces Conference Call to Provide a Corporate Update and First Quarter 2018 Financial Results GlobeNewswire
Apr-12-18 12:00PM  Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at EASL 2018 GlobeNewswire
Apr-11-18 05:24PM  Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic Diseases GlobeNewswire
08:20AM  New Research: Key Drivers of Growth for Talend S.A, Chipmos Technologies, POSCO, Horizon Pharma Public, BioSpecifics Technologies, and Arbutus Biopharma Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-28-18 05:54PM  Arbutus to Present HBV Data at 2018 EASL Liver Meeting GlobeNewswire
Mar-22-18 03:51AM  Edited Transcript of ABUS earnings conference call or presentation 15-May-07 4:00pm GMT Thomson Reuters StreetEvents +7.95%
03:51AM  Edited Transcript of ABUS earnings conference call or presentation 14-Aug-12 8:30pm GMT Thomson Reuters StreetEvents
Mar-19-18 12:57PM  Wedbush Projects Limited Upside For Arbutus Shares This Year, Moves To Sidelines Benzinga -5.71%
Mar-16-18 08:20AM  Report: Developing Opportunities within Capital Product Partners, Adient, Arbutus Biopharma, GW Pharmaceuticals, Customers, and Laureate Education Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-15-18 11:16AM  Edited Transcript of ABUS earnings conference call or presentation 14-Mar-18 8:30pm GMT Thomson Reuters StreetEvents -7.08%
Mar-14-18 04:00PM  Arbutus Announces Corporate Update and Year-End 2017 Financial Results GlobeNewswire -5.83%
10:22AM  Arbutus Biopharma Corporation (NASDAQ:ABUS) Is Expected To Breakeven Simply Wall St.
Mar-12-18 09:00AM  Arbutus Announces Conference Call to Provide a Corporate Update and Fourth Quarter 2017 Year-End Financial Results GlobeNewswire
Feb-22-18 04:35PM  Arbutus Settles Litigation, Terminating Acuitas Rights to LNP Technology GlobeNewswire
Feb-14-18 08:50PM  Arbutus Enters Exclusivity Agreement with Roivant Sciences GlobeNewswire
Feb-13-18 09:36PM  Arbutus Announces Departure of Chief Financial Officer; Appoints Interim CFO GlobeNewswire +6.60%
Feb-08-18 08:30AM  Arbutus Consolidates HBV Business Around Warminster, PA Site GlobeNewswire
Feb-05-18 03:39PM  Should Arbutus Biopharma Corporations (NASDAQ:ABUS) Recent Earnings Decline Worry You? Simply Wall St.
Jan-16-18 08:30AM  Arbutus Announces Closing of the Second Tranche of a $116M Strategic Investment from Roivant Sciences GlobeNewswire
Nov-28-17 07:18AM  Arbutus Biopharma Corp. breached its 50 day moving average in a Bullish Manner : ABUS-US : November 28, 2017 Capital Cube -7.81%
Nov-27-17 09:00AM  Arbutus Announces Presentations at HepDART 2017 GlobeNewswire +5.79%
Nov-16-17 01:40PM  Arbutus LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran GlobeNewswire
Nov-13-17 05:22PM  Arbutus LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA) GlobeNewswire
Nov-08-17 06:35AM  Edited Transcript of ABUS earnings conference call or presentation 2-Nov-17 8:15pm GMT Thomson Reuters StreetEvents
Nov-07-17 08:16AM  Arbutus Biopharma Corp. :ABUS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017 Capital Cube -7.38%
Nov-06-17 07:15AM  Arbutus Biopharma Corp. breached its 50 day moving average in a Bullish Manner : ABUS-US : November 6, 2017 Capital Cube -6.15%
Nov-02-17 04:00PM  Arbutus Announces Corporate Update and Third Quarter 2017 Financial Results GlobeNewswire
10:30AM  Arbutus Biopharma Corporation to Host Earnings Call ACCESSWIRE
Nov-01-17 11:25AM  Should You Buy Arbutus Biopharma Corporation (ABUS)? Simply Wall St.
Oct-31-17 06:16PM  Arbutus Announces Conference Call to Provide a Corporate Update and Third Quarter 2017 Financial Results GlobeNewswire -5.83%
Oct-27-17 11:29AM  Arbutus Biopharma Corp. Value Analysis (NASDAQ:ABUS) : October 27, 2017 Capital Cube +9.01%
Oct-26-17 08:19AM  Arbutus Biopharma Corp. breached its 50 day moving average in a Bearish Manner : ABUS-US : October 26, 2017 Capital Cube
Oct-24-17 08:00AM  Arbutus Presents HBV Data at 2017 AASLD Liver Meeting GlobeNewswire -6.00%
Oct-18-17 12:55PM  Bucks biopharm firm signs licensing deal with California onco-immunology company American City Business Journals
08:00AM  Gritstone Oncology and Arbutus Biopharma Announce LNP Technology Licensing Agreement to Develop Novel RNA-Based Personalized Neoantigen Immunotherapies for Cancer Patients GlobeNewswire
Oct-16-17 10:30AM  Arbutus Announces Closing of $50 Million First Tranche of $116.4 Million Strategic Investment from Roivant Sciences GlobeNewswire
Oct-10-17 08:00AM  Arbutus to Participate in Upcoming Investor Conferences GlobeNewswire
Oct-03-17 08:00AM  Arbutus to Present HBV Data at 2017 AASLD Liver Meeting GlobeNewswire
Oct-02-17 08:20AM  Roivant Makes $116 Million Investment In Arbutus, Backing Battle With Moderna Forbes +16.94%
07:00AM  Arbutus to Receive $116 Million Strategic Investment from Roivant Sciences GlobeNewswire
Sep-25-17 10:00AM  Arbutus to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
08:00AM  Arbutus Announces Topline Results for ARB-1467 Phase II Cohort 4 GlobeNewswire
Sep-22-17 04:54PM  Arbutus Presents HBV Data at Upcoming Scientific Conferences GlobeNewswire -6.43%
Sep-21-17 08:20AM  Today's Research Reports on Stocks to Watch: Alnylam Pharmaceuticals and Arbutus Biopharma ACCESSWIRE
Sep-20-17 12:23PM  Arbutus LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program GlobeNewswire +20.72%
08:57AM  Is It Too Late To Buy Arbutus Biopharma Corporation (ABUS)? Simply Wall St.
Sep-13-17 06:02PM  Alexion to Restructure Operations, to Lower Headcount by 20% Zacks
Sep-12-17 09:00AM  Arbutus: Potential Near-Term Catalysts and Pipeline Overview ACCESSWIRE
Sep-07-17 11:00AM  Arbutus to Host Live Webinar on Developments of LNP Delivery for mRNA-based Therapeutics GlobeNewswire
Aug-24-17 10:27AM  Arbutus Biopharma Corp. :ABUS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-14-17 09:00AM  Arbutus to Present at 2017 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-12-17 10:10PM  Edited Transcript of ABUS earnings conference call or presentation 3-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-03-17 04:00PM  Arbutus Announces Corporate Update and Second Quarter 2017 Financial Results GlobeNewswire -5.56%
12:00PM  Investor Network: Arbutus Biopharma Corporation to Host Earnings Call ACCESSWIRE
Aug-01-17 04:30PM  Arbutus Announces Conference Call to Provide a Corporate Update and Second Quarter 2017 Financial Results GlobeNewswire +5.80%
Jul-27-17 07:00AM  Arbutus Announces Conclusion of LNP License Agreement with Alexion GlobeNewswire -6.67%
Jun-02-17 08:00AM  Arbutus to Participate in Upcoming Investor Conferences GlobeNewswire
May-22-17 07:00AM  Arbutus Presents HBV Drug Combination Studies at ICAR GlobeNewswire
May-16-17 12:01PM  Moderna Can't Escape My Intellectual Property, Says Arbutus CEO Forbes
May-12-17 03:05AM  Edited Transcript of ABUS earnings conference call or presentation 4-May-17 8:30pm GMT Thomson Reuters StreetEvents
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The company's lead candidate is ARB-1467, which is in a Phase II trial to block production of HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also include AB-423, a core protein inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection; and AB-452, an HBV RNA Destabilizer, which is in preclinical study. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates comprising N-Acetylgalactosamine conjugate technology, cccDNA targeting agents, and checkpoint inhibition. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) that has been completed Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and RNA-based neoantigen immunotherapy products. The company has strategic alliance, licensing, and research collaboration agreements with Acuitas Therapeutics Inc.; Spectrum Pharmaceuticals, Inc.; Marina Biotech Inc.; U.S. National Institutes of Health; and The Baruch S. Blumberg Institute and Drexel University. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Murray Mark J.DirectorNov 28Option Exercise1.3525,00033,750341,396Nov 30 04:55 PM
Sofia Michael J.Chief Scientific OfficerAug 13Sale9.514,25040,4361,499,153Aug 14 06:23 PM
Sofia Michael J.Chief Scientific OfficerJul 11Sale10.0010,000100,0001,503,403Jul 13 01:36 PM
Sofia Michael J.Chief Scientific OfficerJul 09Sale8.9110,00089,0601,513,403Jul 10 01:11 PM
Sofia Michael J.Chief Scientific OfficerJul 06Sale8.4510,00084,5001,523,403Jul 10 01:11 PM
Sofia Michael J.Chief Scientific OfficerJul 05Sale8.4010,00084,0001,533,403Jul 06 04:05 PM
Sofia Michael J.Chief Scientific OfficerJul 03Sale8.0010,00080,0001,543,403Jul 06 04:05 PM
Murray Mark J.President & CEOApr 17Option Exercise0.3527,0079,560316,396Apr 17 08:22 PM
open in yahoo | open in reuters | open in google